Saint Louis, Missouri 63110

  • Retinoblastoma


The purpose of this research study is to determine whether taking either of two low dose drugs that would prevent new blood vessels from growing after stem cell transplant is feasible, and what the side effects of taking each of these drugs after autologous transplant might be. The reason the investigators are looking at these drugs is because one of the things that allows tumors to grow quickly is their ability to stimulate the growth of new blood vessels. By suppressing the growth of new blood vessels after stem cell transplant, the investigators hope to prevent the tumors from coming back or continuing to grow.


Inclusion Criteria: - Patient must have an original diagnosis, benefited by autologous transplantation, confirmed by biopsy* of high-grade glial tumor, low-grade glial tumor, ependymoma, medulloblastoma, primitive neuro-ectodermal tumor (PNET), Wilms' tumor, rhabdomyosarcoma, Ewing's sarcoma, retinoblastoma, or miscellaneous poor-prognosis solid tumors. Lymphomas and other lymphoid malignancies will not be studied in this protocol. * Brain stem glioma patients who have progressed after radiation therapy do not require histologic confirmation. Brain stem gliomas are defined as intrinsic tumors of the pons causing diffuse enlargement. These patients are diagnosed on clinical and radiographic appearance of the lesion and the biopsy requirement will be waived for this group. - Patient must be ≥ 6 months of age and ≤ 21 years of age at the time of study entry. - Patient must have a Karnofsky performance status or Lansky* play status ≥ 50 * For purpose of determining performance scores, wheelchair-bound patients will be considered ambulatory. - Patient must have an adequate supply of stem cells for transplant harvested prior to study enrollment, with adequate supply defined as 3 x 10^6 CD34+ cells/kg for peripheral blood stem cells (PBSC). Cell mobilization method will be left up to the treating physician's discretion and may include mobilization growth factor alone or mobilization after chemotherapy. If patient is unable to mobilize the proper amount of peripheral stem cells, bone marrow may be harvested as the source of hematopoietic stem cells. In this instance, 3 x 10^8 mononuclear cells/kg will be considered adequate. If necessary, a combination of peripheral stem cells and bone marrow can be used. - Prior radiation therapy and/or chemotherapy, including cyclophosphamide, are permitted. - Prior anti-angiogenic therapy, including thalidomide and oral cyclophosphamide, is permitted. - If on corticosteroids for mass effect and/or edema related to the tumor, patient must be on a stable or decreasing dose for at least 2 weeks prior to study entry. - Patient must have a life expectancy > 3 months. - Patient must have an adequate bone marrow reserve as defined by: - Hemoglobin ≥ 8.0 g/dl and - Peripheral absolute neutrophil count (ANC) ≥ 750/mm3 - Patient must have adequate cardiac function tested within 4 weeks of study enrollment as defined by: - Shortening fraction of ≥ 27% by echocardiogram or - Ejection fraction of ≥ 50% by radionuclide angiogram - Patient must have adequate pulmonary function tested within 4 weeks of study enrollment as defined by: - Pulse oximetry > 94% on room air or O2 by nasal cannula and - No evidence of dyspnea at rest. - Patient must have adequate hepatic function as defined by: - Total bilirubin ≤ 1.5x upper limit of normal (ULN) for age and - SGOT (AST) or SGPT (ALT) ≤ 2.5 x ULN (SGOT ≤ 4x ULN if on Zantac) - Patient must have adequate renal function as defined by: - Serum creatinine < 1.5 mg/dl - Glomerular filtration rate (GFR), calculated via I-125 iothalamate clearance, 24-hour creatinine clearance, or Schwartz formula*, ≥ 70 mL/min and ≥ 50 mL/min/1.73 m2 done within 4 weeks of study entry - The Schwartz formula is an estimated glomerular filtration rate in children based upon serum creatinine and height. Height (Ht) should be measured in cm and serum creatinine (Cr) in mg/dL. Proportionality constant (k) is 0.55 for children and adolescent girls and 0.7 for adolescent boys aged 13-21. This constant is based upon a series of evaluations performed by Schwartz. Formula: GFR= (k x Ht)/Cr - Enrollment in the Celgene THALOMID REMSTM Program: 1. If enrolled in Arm III of this study, patient must be registered at the Celgene THALOMID REMSTM Program prior to day +30 post-ASCR. 2. If enrolled in Arm III of this study, patient must be willing to practice birth control as outlined in the THALOMID REMSTM Program from the beginning of the thalidomide treatment until at least 4 weeks following discontinuation of thalidomide therapy. Two reliable forms of contraception must be used simultaneously unless continuous abstinence from heterosexual sexual contact is chosen. Contraceptive methods must include at least one highly effective method (e.g. oral contraceptive pills, injections, hormonal patches, IUD, or implants), AND one additional effective barrier method (e.g. latex condom, diaphragm, cervical cap). If hormonal or IUD contraception is medically contraindicated, another highly effective method or two barrier methods must be used at the same time. 3. Pregnancy surveillance: i. Patient must have a negative in office pregnancy test sensitive to within 50 mIU/mL (serum or urine) within 24 hours prior to beginning thalidomide even if continuous abstinence is the preferred method of birth control. ii. A pregnancy test must be performed weekly during the first 4 weeks of therapy and repeated monthly for patients with regular menses or every 2 weeks for patients with irregular menses iii. Negative pregnancy tests are valid for only 7 days. iv. If irregular bleeding or skipped menses, pregnancy test should be performed and pregnancy counseling given. v. If pregnancy occurs during treatment, thalidomide must be immediately discontinued. Any suspected lethal exposure must be reported immediately to Celgene Customer Care Center at 1-888-423-5346, and the patient referred to an OB/GYN experienced in reproductive toxicity for further evaluation and counseling. - Patient (or legally authorized representative) must be able to understand and willing to sign a written informed consent document. Exclusion Criteria: - Patient must not have any active, uncontrolled cardiac, hepatic, renal, or psychiatric disease defined as ≥ grade 3 based on NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE). - Patient must not be receiving any other investigational agents. - Patient must not have any active infection or concurrent illness obscuring toxicity or dangerously altering drug metabolism. - Patient must not have any thromboembolic event (deep vein thrombosis or pulmonary embolism) less than 3 weeks prior to enrollment. - Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in the study. - Patient must not be pregnant or breastfeeding.

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:


Brief Title:

Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors

Official Title:

Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Pediatric Solid Tumors

Overall Status:


Study Phase:

Phase 1



Minimum Age:

6 Months

Maximum Age:

21 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Washington University School of Medicine

Oversight Authority:

United States: Institutional Review Board

Reasons Why Stopped:

Study Type:


Study Design:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Andrew Cluster, M.D.
Principal Investigator
Washington University School of Medicine
Primary Contact:Andrew Cluster, M.D.

Study Dates

Start Date:October 26, 2012
Completion Date:November 23, 2022
Completion Type:Anticipated
Primary Completion Date:November 23, 2022
Primary Completion Type:Anticipated
Verification Date:June 2020
Last Changed Date:June 15, 2020
First Received Date:July 30, 2012

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Best overall response
Time Frame:86 days
Safety Issues:False
Description:Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1.
Outcome Type:Secondary Outcome
Measure:Radiographic marker of neovascularization
Time Frame:86 days
Safety Issues:False
Description:Measurement of anti-angiogenic activity in the treatment of solid tumors from baseline to Day +86.
Outcome Type:Primary Outcome
Measure:Incidence of major transplant related toxicities (Grades IV and IV)
Time Frame:Within the first year of transplant
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Safety as measured by absence of grade 4 or 5 non-hematological or grade 5 hematological toxicity
Time Frame:Through 1 year post-transplant
Safety Issues:False

Study Interventions

Intervention Type:Drug
Arm Name:Thalidomide
Other Name:Thalomid®
Intervention Type:Drug
Name:Metronomic Cyclophosphamide
Arm Name:Metronomic Cyclophosphamide
Other Name:Cytoxan®

Study Arms

Study Arm Type:Experimental
Arm Name:Thalidomide
Description:Thalidomide will be initiated at 3mg/kg PO daily beginning Day + 30 (30 days post transplant) and continue until Day +86
Study Arm Type:Experimental
Arm Name:Metronomic Cyclophosphamide
Description:Cyclophosphamide will be given PO once daily at 2.5 mg/kg/day for children < 40kg or 100 mg daily for children > 40kg beginning Day + 30 (30 days post transplant) and continue until at least Day +86
Study Arm Type:No Intervention
Arm Name:Control
Description:No intervention

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Washington University School of Medicine

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source:

Date Processed: September 24, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

If you would like to be contacted by the clinical trial representative please fill out the form below.